Tai-Wei Ho
Co-Founder, CEO & DirectorMr. William Ho, also known as Will, is the Co-Founder of IN8bio, Inc. and has been Chief Executive Officer and Director since November 2015 and served as its President since November 2015 and had been its Chief Financial Officer since October 2020. Prior to this, from April 2014 to November 2017, Mr. Ho was the founder and Managing Partner at AlephPoint Capital. Mr. Ho was Consultant at New Leaf Venture Partners. He has experience in biotechnology industry. He joined AlephPoint Capital in January 2011 as a Public Investment Director. Mr. Ho served as senior healthcare strategist on a derivatives desk at ICAP plc. He served as Senior Research Analyst at Bank of America Corporation. Previously, Mr. Ho worked at Piper Jaffray Companies where he was a Research Analyst covering the biotechnology and life sciences tools sectors. He entered equity research from an operational role at CuraGen Corporation, where he was responsible for financial and operational analysis including the operating budget and several of the company’s restructurings. He was an Associate in the health care investment banking group at SG Cowen. In 2008, Mr. Ho was named the “Best Up-and-Comer“ in the biotechnology sector by Institutional Investor in its All-America Research Team rankings. He received an M.B.A. degree from the University of Notre Dame and a B.S. in Biochemistry, with honors, from McMaster University in Canada.
Positions
- Company NameIN8bio, Inc.Stock CodeINABPositionCo-Founder, CEO & DirectorColleagues
- JRJeremy R. GraffInterim Independent Chair
- KRKate RochlinPresident & COO
- PMPatrick McCallCFO & Secretary
- LSLawrence S. LambExecutive VP, Co-Founder & Chief Scientific Officer
- OPOxana PolyakovaSenior Vice President of Research & Development
- PCPeter C. BrandtIndependent Director
- LGLuba GreenwoodIndependent Director
- EWEmily Wang FairbairnIndependent Director
